| Verified against primary record | |
| Routes without travel | Expanded access in the United States; compassionate use under Article 83 in the European Union[1][2] |
|---|---|
| Approved stem cell products, United States | Blood-forming stem cells from umbilical cord blood only; no approved exosome products[3] |
| Clinical trials abroad | Outside the scope of Directive 2011/24/EU[4] |
| Records read | FDA and EMA publications and the trial access study, 30 September 2026 |
| Independently reported | |
| Volume | No official statistics exist; member states do not collect the data[4] |
| Bands apply only to the rows beneath them. No provider-supplied figures are used. | |
Medical travel for unavailable treatments describes journeys made to obtain an intervention that cannot be had at home, whether because it is unapproved there, because it is approved but not funded, or because it exists only inside a clinical trial that recruits elsewhere. The category spans treatments with strong evidence behind them and treatments with none, and the two are not always easy to tell apart from a clinic’s website.
Routes that do not require travel
Both major regulatory systems maintain a pathway to an unapproved product without leaving the country. The United States Food and Drug Administration describes expanded access, sometimes called compassionate use, as a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product for treatment outside clinical trials when no comparable or satisfactory alternative therapy options are available. Five conditions must all apply, including that enrolment in a clinical trial is not possible and that supplying the product will not interfere with trials supporting its development.[1]
The European equivalent rests on Article 83 of Regulation (EC) No 726/2004 and covers patients with a chronically or seriously debilitating disease, or a life threatening disease, who cannot be treated satisfactorily by an authorised medicinal product.[5] Its practical reach varies, because compassionate use programmes are coordinated and implemented by member states, which set their own rules and procedures, and the Agency’s committee opinions do not create a legal framework.[2] The Regulation’s own recitals record the ambition that a common approach should be followed, whenever possible, on the criteria and conditions for compassionate use under member states’ legislation.[6] That the approach remains national rather than common is itself one reason a patient may look across a border.
Clinical trials
Travelling to join a trial is legally distinct from travelling for treatment. A 2020 study of cross-border trial access in the European Union records that participation in a clinical trial in another member state or outside the Union is not within the scope of Directive 2011/24/EU, so the Directive’s reimbursement route does not apply to it.[4] The same study found that such participation occurs in practice but very rarely, with 75 per cent of respondents reporting it as rare and 92 per cent believing it should be facilitated. Financial and logistical burden was the most frequently cited barrier, named by 81 per cent, ahead of language, distance and follow-up care coordination.[4]
Unproven interventions
The category that draws most regulatory attention is cell-based therapy marketed directly to patients. The Food and Drug Administration states that the only stem cell products approved for use in the United States consist of blood-forming stem cells derived from umbilical cord blood, and that there are currently no approved exosome products.[3] It records having received reports of blindness, tumour formation, infections including life-threatening blood infections, neurological events and unwanted immune responses following unapproved regenerative medicine products, without publishing patient counts for any of them.[7] The European Medicines Agency has warned since 2010 about unregulated products containing stem cells, and in March 2025 stated that unregulated advanced therapy products could put patients at risk while providing no benefit.[8]
A point of accuracy is worth making here, because it is widely got wrong. Five separate Food and Drug Administration consumer and enforcement pages were read for this entry. None of them mentions travelling abroad, receiving treatment in another country, or medical tourism.[3][7] The agency’s warnings concern products marketed and administered inside the United States, at domestic clinics, and products bought online. The frequently repeated statement that the agency warns patients against travelling abroad for stem cell treatment is not supported by its own consumer-facing publications. The best-known cases of blindness following such treatment likewise arose at a Florida clinic and were the subject of United States enforcement, not of medical travel.
Documented harm following treatment obtained abroad does exist, but the published record is thin. A 2021 case report describes a 48-year-old man with end-stage kidney failure who received an intravenous infusion at a clinic in Ukraine in December 2018, developed necrotising skin ulcers, cholestatic hepatitis and worsening cardiomyopathy over the following six months, and died.[9] It is a single case in a patient with substantial existing disease, and it supports no claim about frequency.
Scale
How many people travel for treatments unavailable at home is not known. On the trial side the position is stated explicitly: there are no official statistics, and member states do not collect statistical data about patients who seek participation in a trial abroad.[4] For unproven therapies the academic literature counts businesses offering them rather than patients reaching them. No figure in circulation for this category traces back to a measurement.
See also
- Medical travel for rare diseases, the neighbouring case where expertise rather than the treatment is missing
- Emergency healthcare abroad, care sought abroad without prior planning
- Self-funded medical travel, the payment route most of this travel uses
- Medical tourism and public health, for the population-level view of unregulated care
References
- United States Food and Drug Administration. Expanded Access. Last updated 8 September 2025. Verified against primary record: regulator page opened and read. Retrieved 30 September 2026.
- European Medicines Agency. Compassionate use. Verified against primary record: regulator page opened and read. Retrieved 30 September 2026.
- United States Food and Drug Administration. Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. 9 April 2024. Verified against primary record: regulator page opened and read. Retrieved 30 September 2026.
- Lalova T, Padeanu C, Negrouk A, Lacombe D, Geissler J, Klingmann I, Huys I. Cross-border access to clinical trials in the EU: Exploratory study on needs and reality. Frontiers in Medicine, vol. 7, article 585722, 2020. Independently reported: peer-reviewed study. Retrieved 30 September 2026.
- European Medicines Agency. Guideline on Compassionate Use of Medicinal Products, Pursuant to Article 83 of Regulation (EC) No 726/2004. EMEA/27170/2006, 19 July 2007. Verified against primary record: regulator guideline opened and read. Retrieved 30 September 2026.
- European Parliament and Council. Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products. OJ L 136/1, 30 April 2004, recital 33. Verified against primary record: Official Journal text read. Retrieved 30 September 2026.
- United States Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Last updated 8 April 2024. Verified against primary record: regulator page opened and read. Retrieved 30 September 2026.
- European Medicines Agency. Unregulated advanced therapy medicinal products pose serious risks to health. 13 March 2025. Verified against primary record: regulator news item opened and read. Retrieved 30 September 2026.
- Veceric-Haler Z, Borstnar S, Luzar B, Jerse M, Kojc N. Multiorgan failure with fatal outcome after stem cell tourism. European Journal of Medical Research, vol. 26, article 5, 2021. Independently reported: peer-reviewed case report. Retrieved 30 September 2026.
Sourcing note: the regulator publications and the trial access study were opened and read on 30 September 2026. The statement that the United States regulator does not warn about travelling abroad for stem cell treatment rests on reading five of its consumer and enforcement pages in full and finding no such reference; it is a statement about what those pages contain, not a claim that no such warning exists anywhere. The 2010 European statement that no stem cell medicinal product had then been authorised is sixteen years old and is not reproduced here as current. The case report is a single case and is presented as one.